Amicus Therapeutics Q4 2024 Earnings Report
Key Takeaways
Amicus Therapeutics reported Q4 2024 revenue of $149.7 million, a 30% increase year-over-year. Net income for the quarter was $14.7 million, a significant improvement from a loss of $33.8 million in Q4 2023. Non-GAAP net income was $29.2 million, with a non-GAAP EPS of $0.10. The company continues to expand its commercial presence for Pombiliti + Opfolda and anticipates achieving positive GAAP net income during H2 2025.
Q4 2024 revenue grew 30% YoY to $149.7 million.
Galafold sales increased by 20% to $127.5 million in Q4.
Pombiliti + Opfolda sales surged 162% YoY, reaching $22.2 million.
Q4 GAAP net income was $14.7 million, reversing a prior-year loss.
Amicus Therapeutics Revenue
Amicus Therapeutics EPS
Amicus Therapeutics Revenue by Segment
Forward Guidance
Amicus Therapeutics projects total revenue growth of 17% to 24% in 2025, with continued expansion in Pombiliti + Opfolda sales and positive GAAP net income expected in the second half of 2025.
Positive Outlook
- Total revenue projected to grow 17% to 24% in 2025.
- Galafold revenue expected to increase 10% to 15%.
- Pombiliti + Opfolda growth forecasted between 65% and 85%.
- Company aims to surpass $1 billion in revenue by 2028.
- Continued expansion in international markets with new regulatory approvals.
Challenges Ahead
- Operating expenses projected between $350M and $370M in 2025.
- Potential risks related to pricing and reimbursement negotiations.
- Market conditions and foreign exchange impacts may affect revenue.
- Increased competition in the rare disease treatment market.
- Regulatory approval timelines may impact commercialization strategy.